(Q30867916)

27 June 2017

1 reference

title

Quetiapine for schizophrenia. (English)

1 reference

27 June 2017

Quetiapine for schizophrenia (English)

0 references

1 reference

M Srisurapanont

1

1 reference

27 June 2017

C Disayavanish

series ordinal

2

1 reference

27 June 2017

K Taimkaew

series ordinal

3

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

27 June 2017

2000

0 references

published in

1 reference

27 June 2017

issue

2

1 reference

27 June 2017

3

0 references

page(s)

CD000967

1 reference

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

Seroquel (ICI 204 636), a putative “atypical” antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

Should unpublished data be included in meta-analyses? Current convictions and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

Seroquel: electrophysiological profile of a potential atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

What are pragmatic trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

Seroquel: biochemical profile of a potential atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

Effects of 'Seroquel' (quetiapine) on platelet serotonin-2 binding in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

Medical-claims databases in the design of a health-outcomes comparison of quetiapine ('Seroquel') and usual-care antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967

10.1002/14651858.CD000967

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference